Skip to main content
Industry News
AZ's osimertinib gains breakthrough therapy tag
7/31/2020

AstraZeneca's Tagrisso, or osimertinib, has been tagged for accelerated review after receiving breakthrough therapy status from the FDA. The drug is an adjuvant treatment for patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer who have undergone complete tumor resection.

Full Story: